Arcus Biosciences Shares Hit 52-Week Low After $150M Stock Offering
Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the session, and are down 33% in the past 12 months.
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
One thing we could say about the analysts on Arcus Biosciences, Inc. (NYSE:RCUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
Arcus Biosciences (RCUS) announced the pricing of an underwritten offering of 13,636,364 shares of its common stock at an offering price of ...
Shares of Arcus Biosciences (NYSE:RCUS) hit a new 52-week low on Tuesday after the biotech said that Gilead Sciences’ (NASDAQ:GILD) option rights to partner with the company for a potential anticancer ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...
Arcus Capital Partners LLC boosted its position in Meta Platforms, Inc. (NASDAQ:META – Free Report) by 6.9% during the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback